论文部分内容阅读
背景:利妥昔单抗自1997年以来常被用于治疗复发性低度恶性或晚期非霍奇金淋巴瘤,药物靶点为由B细胞表达的CD20抗原。利妥昔单抗单一疗法安全且耐受性好。经利妥昔单抗治疗后的复发病例出现CD20表达缺失之前曾有报道。方法:4例CD20阳性皮肤B细胞淋巴瘤患者接受利妥昔单抗治疗后
BACKGROUND: Rituximab is often used to treat recurrent low-grade or advanced non-Hodgkin’s lymphoma since 1997. Drug targets are CD20 antigens expressed by B cells. Rituximab monotherapy is safe and well tolerated. Rituximab treatment after recurrence of cases of CD20 expression was previously reported. METHODS: Four patients with CD20-positive cutaneous B-cell lymphoma were treated with rituximab